Skip to main content
PRESCIENT THERAPEUTICS LIMITED logo

PRESCIENT THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PTX ISIN · AU000000PTX3 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2025-03-25 Capital/Financing Update
Country AU Australia
Listing ASX PTX

About PRESCIENT THERAPEUTICS LIMITED

https://ptxtherapeutics.com/

Prescient Therapeutics Limited is a clinical-stage oncology company focused on developing personalized medicine and innovative cancer treatments. The company leverages two primary technology pillars: modular cell therapies and targeted small molecule inhibitors. Its flagship OmniCAR platform is a universal, multi-arm CAR-T system designed to provide clinicians with enhanced control and flexibility over cell therapy treatments, addressing limitations such as antigen escape and toxicity. Complementing this is the CellPryme platform, which optimizes cell therapy performance through improved manufacturing and efficacy. Additionally, Prescient maintains a pipeline of targeted therapies, including PTX-100, a first-in-class prenylation inhibitor targeting the Ras pathway, and PTX-200, an AKT inhibitor. These programs aim to treat various hematological malignancies and solid tumors by addressing specific genetic drivers of cancer.

Recent filings

Filing Released Lang Actions
PTX Opens First Clinical site for PTX-100 Phase 2a Study 4 pages 195.8KB
Capital/Financing Update Classification · 85% confidence The document is a press release announcing the initiation of the first clinical site for a Phase 2a study of PTX-100 by Prescient Therapeutics. It highlights a milestone in clinical development, provides background on the drug and company, and invites investors to an online briefing. There are no financial statements, regulatory filings, voting results, or detailed management discussions. The content is primarily an operational update and investor announcement about clinical trial progress and an upcoming briefing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a presentation or transcript but an announcement of a clinical milestone and investor event. Therefore, the best fitting category is Capital/Financing Update (CAP), as it relates to development progress and investor communication about a clinical trial milestone, which is often grouped under capital or financing updates in biotech companies.
2025-03-25 English
Change of Chief Medical Officer 4 pages 157.8KB
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of a new Chief Medical Officer at Prescient Therapeutics Limited. It includes biographical details about the new appointee, a summary of the company's clinical programs, and an invitation to an investor briefing. There are no financial statements, regulatory filings, or detailed financial performance data included. The content focuses on management changes at the senior executive level. Therefore, this document fits the category of Board/Management Information (MANG). The document length is sufficient and contains substantive information about the management change, not just a brief notice or a report publication announcement.
2025-03-23 English
PTX-100 clinical data presented at leading TCL meeting 4 pages 166.8KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the presentation of clinical data from a Phase 1b study of PTX-100 at an international medical meeting. It discusses clinical trial results, upcoming Phase 2 study plans, and company information. There are no financial statements, regulatory filings, or detailed financial data. The content is primarily an update on clinical development and upcoming presentations rather than a formal financial or regulatory report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an announcement of clinical data presentation and company progress, which aligns best with a general Regulatory Filing (RNS) as a miscellaneous announcement that does not fit other specific categories.
2025-03-20 English
Change of Director's Interest Notice 3 pages 239.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number of shares held before and after the change, the nature of the interest, and transaction details. This type of document is a formal notification of personal share transactions by a company director, commonly known as a director's dealing report. The document length is 4377 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is an earnings release, annual report, or any other type of filing. Therefore, the correct classification is Director's Dealing (DIRS).
2025-03-16 English
Change of Board Chair 3 pages 243.2KB
Board/Management Information Classification · 100% confidence The document is an announcement regarding a change in the company's board chair, detailing the retirement of the current chair and the appointment of a new chair. It includes biographical and strategic comments but does not contain financial statements, audit information, or detailed management discussion of financial results. There is no indication of it being a full annual or interim report, earnings release, or any other financial filing. The content focuses on board and senior management changes, which aligns with the category for announcements about changes in the company's board of directors or senior management. The document length is over 10,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-03-10 English
Appendix 4D and Half Year Financial Report 19 pages 850.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Prescient Therapeutics Limited Appendix 4D Half-year report' and references the half-year ended 31 December 2024. It contains detailed financial statements including profit or loss, financial position, directors' report, auditor's review report, and notes to the financial statements. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, specifically a half-year report. The presence of an auditor's review report and detailed financial statements confirms this is a substantive interim financial report rather than a mere announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-02-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.